|
1
|
Larrey D: Drug-induced hepatitis:
Epidemiologic, clinical, diagnostic and physiopathologic aspects in
1995. Rev Med Interne. 16:752–758. 1995.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kaplowitz N: Drug-induced liver injury.
Clin Infect Dis. 38:(Suppl 2). S44–S48. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Russmann S, Jetter A and Kullak-Ublick GA:
Pharmacogenetics of drug-induced liver injury. Hepatology.
52:748–761. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
McGill MR and Jaeschke H: MicroRNAs as
signaling mediators and biomarkers of drug- and chemical-induced
liver injury. J Clin Med. 4:1063–1078. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ward J, Kanchagar C, Veksler-Lublinsky I,
Lee RC, McGill MR, Jaeschke H, Curry SC and Ambros VR: Circulating
microRNA profiles in human patients with acetaminophen
hepatotoxicity or ischemic hepatitis. Proc Natl Acad Sci USA.
111:12169–12174. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Danan G and Benichou C: Causality
assessment of adverse reactions to drugs - I. A novel method based
on the conclusions of international consensus meetings: Application
to drug-induced liver injuries. J Clin Epidemiol. 46:1323–1330.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lucena MI, Andrade RJ, Kaplowitz N,
García-Cortes M, Fernández MC, Romero-Gomez M, Bruguera M, Hallal
H, Robles-Diaz M, Rodriguez-González JF, et al: Spanish Group for
the Study of Drug-Induced Liver Disease: Phenotypic
characterization of idiosyncratic drug-induced liver injury: The
influence of age and sex. Hepatology. 49:2001–2009. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chalasani N and Björnsson E: Risk factors
for idiosyncratic drug-induced liver injury. Gastroenterology.
138:2246–2259. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhu Y, Li YG, Wang JB, Liu SH, Wang LF,
Zhao YL, Bai YF, Wang ZX, Li JY and Xiao XH: Causes, features, and
outcomes of drug-induced liver injury in 69 children from China.
Gut Liver. 9:525–533. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma X, Peng JH and Hu YY: Chinese Herbal
Medicine-induced Liver Injury. J Clin Transl Hepatol. 2:170–175.
2014.PubMed/NCBI
|
|
11
|
Navarro VJ and Senior JR: Drug-related
hepatotoxicity. N Engl J Med. 354:731–739. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Daly AK: Pharmacogenomics of adverse drug
reactions. Genome Med. 5:52013. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Douros A, Bronder E, Andersohn F, Klimpel
A, Thomae M, Sarganas G, Kreutz R and Garbe E: Drug-induced liver
injury: Results from the hospital-based Berlin case-control
surveillance study. Br J Clin Pharmacol. 79:988–999. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Patin E, Harmant C, Kidd KK, Kidd J,
Froment A, Mehdi SQ, Sica L, Heyer E and Quintana-Murci L:
Sub-Saharan African coding sequence variation and haplotype
diversity at the NAT2 gene. Hum Mutat. 27:7202006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim SH, Kim SH, Bahn JW, Kim YK, Chang YS,
Shin ES, Kim YS, Park JS, Kim BH, Jang IJ, et al: Genetic
polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced
hepatitis. Pharmacogenomics. 10:1767–1779. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen M, Borlak J and Tong W: High
lipophilicity and high daily dose of oral medications are
associated with significant risk for drug-induced liver injury.
Hepatology. 58:388–396. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maddox JF, Amuzie CJ, Li M, Newport SW,
Sparkenbaugh E, Cuff CF, Pestka JJ, Cantor GH, Roth RA and Ganey
PE: Bacterial- and viral-induced inflammation increases sensitivity
to acetaminophen hepatotoxicity. J Toxicol Environ Health A.
73:58–73. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Russo MW and Watkins PB: Are patients with
elevated liver tests at increased risk of drug-induced liver
injury? Gastroenterology. 126:1477–1480. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zamor PJ and Russo MW: Liver function
tests and statins. Curr Opin Cardiol. 26:338–341. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Baig NA, Herrine SK and Rubin R: Liver
disease and diabetes mellitus. Clin Lab Med. 21:193–207.
2001.PubMed/NCBI
|
|
21
|
Oda S and Yokoi T: Establishment of animal
models of drug-induced liver injury and analysis of possible
mechanisms. Yakugaku Zasshi. 135:579–588. 2015.(In Japanese).
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chinese Society for Tuberculosis and
Chinese Medical Association, . Recommendations for diagnosis and
treatment of anti-tuberculosis drug induced liver injury. Chin J
Tuberc Respir Dis. 36:732–736. 2013.
|
|
23
|
He LN, Yang AH, Cui TY, Zhai YR, Zhang FL,
Chen JX, Jin CH, Fan YW, Wu ZJ, Wang LL, et al: Reactive metabolite
activation by CYP2C19-mediated rhein hepatotoxicity. Xenobiotica.
45:361–372. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cotreau MM, von Moltke LL and Greenblatt
DJ: The influence of age and sex on the clearance of cytochrome
P450 3A substrates. Clin Pharmacokinet. 44:33–60. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lewis JH, Mortensen ME, Zweig S, Fusco MJ,
Medoff JR and Belder R: Pravastatin in Chronic Liver Disease Study
Investigators: Efficacy and safety of high-dose pravastatin in
hypercholesterolemic patients with well-compensated chronic liver
disease: Results of a prospective, randomized, double-blind,
placebo-controlled, multicenter trial. Hepatology. 46:1453–1463.
2007. View Article : Google Scholar : PubMed/NCBI
|
